Erbitux (North America) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Erbitux (North America) General Information

Description

Portfolio of rights related to the pharmaceutical product Erbitux (cetuximab). The rights include, but are not limited to, full commercialization and manufacturing operational responsibilities. Erbitux is an epidermal growth factor receptor antagonist which provides treatments for gastrointestinal, colorectal, head and neck cancers.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Biotechnology
Pharmaceuticals
Acquirer
Primary Office
  • 345 Park Avenue
  • New York, NY 10154
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Erbitux (North America) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Erbitux (North America)‘s full profile, request access.

Request a free trial

Erbitux (North America) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Erbitux (North America)‘s full profile, request access.

Request a free trial